PDS Biotechnology (PDSB) AI Stock Analysis

• Market Cap: $52.15M
• Dividend Yield: N/A
• Average Volume (3M): 507.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.40
• Revenue Growth: N/A
• EPS Growth: 29.95%
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.19
• Shares Outstanding: 54,721,306
• 10 Day Avg. Volume: 403,296
• 30 Day Avg. Volume: 507,388
• PEG Ratio: 0.06
• Price to Book (P/B): 3.13
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.69
• Enterprise Value/Market Cap: 0.75
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -2.59K
• Enterprise Value/Ebitda: -1.27
• 1Y Price Target: $9.00
• Price Target Upside: 809.09% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.68
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: $1.00 ▲(0.81% Upside)

The score is held down primarily by weak financial performance (no revenue, ongoing losses, substantial cash burn, and a reduced equity base versus debt). Partially offsetting this are moderately improving technical momentum and generally positive clinical/regulatory updates from the earnings call and recent corporate events, though funding and trial-timing risks remain key.

Positive Factors

Strong Phase 2 efficacy (VERSATILE-002)

Robust mOS in VERSATILE-002 versus historical controls provides durable clinical proof-of-concept for PDS0101. Strong survival data supports regulatory discussions, partnership interest, and long-term commercial positioning in HPV16 HNSCC, reducing scientific risk through late-stage development.

Regulatory pathway advancement (PFS amendment)

Amending VERSATILE-003 to use PFS as a primary endpoint can materially shorten time to an approvable signal, lowering development duration and costs. Structurally this could de‑risk the timeline to market and improve cash efficiency, even while mOS remains the full approval endpoint.

Strengthened intellectual property

New composition‑of‑matter and methods patents in Japan extend global exclusivity into the 2040s. Durable IP protection enhances long‑term commercial upside, supports licensing/partnering leverage, and deters generic competition across key markets for a future approved product.

Negative Factors

No product revenue, persistent losses

Zero revenue and substantial recurring operating losses mean ongoing reliance on external capital. Over multiple quarters this structurally increases dilution and constrains strategic choices, forcing prioritization of programs and potentially slowing development absent durable funding or partner revenue streams.

Eroded equity base and material debt

Sharply reduced equity alongside meaningful debt weakens financial flexibility and increases leverage risk. Structurally this limits capacity to absorb trial delays or fund expansions, heightens refinancing needs, and may force dilutive financings or unfavorable terms with partners or lenders.

High cash burn and funding dependence

Rapid depletion of cash and reliance on equity financings are durable operational risks. Continuous burn pressures runway, increases likelihood of further dilution, and can delay trials or regulatory activities if new capital is slow or costly, constraining long‑term program execution.

PDS Biotechnology Business Overview & Revenue Model

Company Description

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

How the Company Makes Money

PDS Biotechnology primarily generates revenue through strategic partnerships, collaborations, and licensing agreements with larger pharmaceutical companies and research institutions. These partnerships often involve milestone payments and royalties based on the development and commercialization of their Versamune®-based products. Additionally, the company may receive funding from government grants and research subsidies aimed at supporting advancements in cancer immunotherapy and vaccine development. As a clinical-stage company, PDS Biotech is still in the process of moving its products through clinical trials, with the potential for future revenue from product sales upon successful market approval.

PDS Biotechnology Financial Statement Overview

Summary

PDS Biotechnology's financials are typical of an early-stage biotech firm, with no revenue and ongoing losses due to high R&D costs. The strong cash position provides some immediate liquidity relief, but the negative cash flow and increasing debt highlight the need for future revenue generation. The reliance on external financing is a risk without clear paths to profitability.

Income Statement

PDS Biotechnology has reported no revenue over the last several years, indicating that the company is still in the development phase common to biotech firms. The absence of revenue and persistent negative EBIT and net income show ongoing operational losses. This is typical for biotech companies in early stages, but it poses significant financial risks if such trends continue without the introduction of revenue-generating products.

Balance Sheet

The company's balance sheet shows a relatively strong cash position with significant cash and short-term investments exceeding total debt, resulting in negative net debt, which is a positive indicator of liquidity. However, the equity has been declining due to ongoing losses, and the debt-to-equity ratio has increased over time, indicating rising leverage. The company’s equity ratio remains positive, reflecting more assets funded by equity than debt, but the trend suggests potential future financial strain.

Cash Flow

Free cash flow is consistently negative, reflecting high cash burn typical of biotech firms without revenue. Operating cash flow is negative and significantly exceeds net income, suggesting that operational activities consume more cash than they generate. The reliance on financing activities for cash flow stability poses a risk if external funding becomes less accessible.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-15.13K	-59.79K	-57.33K	0.00	0.00	0.00
EBITDA	-30.71M	-33.75M	-40.09M	-40.74M	-21.43M	-14.89M
Net Income	-34.88M	-37.61M	-42.94M	-40.85M	-16.92M	-14.85M
Balance Sheet
Total Assets	34.71M	45.36M	59.39M	77.01M	67.20M	30.89M
Cash, Cash Equivalents and Short-Term Investments	26.20M	41.69M	56.56M	73.82M	65.24M	28.84M
Total Debt	17.97M	21.83M	23.85M	23.47M	490.35K	610.26K
Total Liabilities	25.25M	26.35M	33.26M	33.01M	3.99M	3.76M
Stockholders Equity	9.45M	19.00M	26.13M	44.00M	63.21M	27.13M
Cash Flow
Free Cash Flow	-32.28M	-35.06M	-33.64M	-25.71M	-12.49M	-13.15M
Operating Cash Flow	-32.28M	-35.03M	-33.64M	-25.71M	-12.49M	-13.15M
Investing Cash Flow	0.00	-29.00K	0.00	0.00	0.00	0.00
Financing Cash Flow	8.73M	20.19M	16.38M	34.29M	48.89M	29.83M

PDS Biotechnology Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.99
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PDSB, the sentiment is Positive. The current price of 0.99 is above the 20-day moving average (MA) of 0.90, above the 50-day MA of 0.88, and below the 200-day MA of 1.14, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 60.84 is Neutral, neither overbought nor oversold. The STOCH value of 83.36 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PDSB.

PDS Biotechnology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LTRN	52 Neutral	$38.14M	-1.93	-104.58%	―	―	1.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PDSB	51 Neutral	$52.15M	-1.21	-221.81%	―	―	29.95%
CALC	51 Neutral	$83.29M	-3.32	-526.36%	―	―	-2.46%
MRSN	48 Neutral	$145.36M	-2.06	―	―	-4.76%	8.09%
SNTI	48 Neutral	$30.23M	-0.32	-394.62%	―	―	78.60%
TPST	43 Neutral	$13.85M	-0.29	-405.03%	―	―	49.43%

PDS Biotechnology Corporate Events

PDS Biotechnology Updates Phase 3 Trial Design for PDS0101

On January 9, 2026, PDS Biotechnology announced it had submitted a protocol amendment to the U.S. Food and Drug Administration for its Phase 3 VERSATILE-003 trial of PDS0101 in HPV16-positive recurrent and/or metastatic head and neck cancer, following a constructive Type C meeting with the agency in December 2025. The amendment designates progression-free survival as the primary endpoint that can be evaluated earlier, potentially shortening trial duration and supporting an accelerated approval pathway, while median overall survival and safety remain key requirements for full approval, a move underpinned by positive final results from the earlier VERSATILE-002 study showing promising survival and durable progression-free outcomes.

The most recent analyst rating on (PDSB) stock is a Hold with a $0.80 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.

PDS Biotechnology Secures New Patent for PDS0101

On December 9, 2025, PDS Biotechnology Corporation announced that the Japan Patent Office issued a new patent for PDS0101, expanding its intellectual property estate. This development strengthens the company’s global IP portfolio, providing patent and market protections for PDS0101 into the 2040s, and supports the company’s growth as it advances its pipeline worldwide.

The most recent analyst rating on (PDSB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.

PDS Biotechnology Gains FDA Meeting for PDS0101 Approval

On December 2, 2025, PDS Biotechnology announced that the FDA accepted its request for a Type C Meeting to discuss an accelerated approval pathway for its PDS0101 treatment in HPV16-positive head and neck cancer. This meeting, scheduled for December 2025, aims to explore amendments to the Phase 3 VERSATILE-003 trial, potentially expediting the treatment’s availability to patients based on positive results from the VERSATILE-002 trial.

The most recent analyst rating on (PDSB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.

PDS Biotechnology Announces $11.1M Securities Purchase Agreement

On November 11, 2025, PDS Biotechnology Corporation announced a securities purchase agreement to raise up to $11.1 million through the sale of common stock and warrants, with the offering expected to close on November 12, 2025. The proceeds will support the company’s ongoing VERSATILE-003 Phase 3 clinical trial and other research and development activities, potentially impacting its operational capabilities and market position.

The most recent analyst rating on (PDSB) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.

PDS Biotechnology Announces Positive Data at Cancer Meeting

On November 10, 2025, PDS Biotechnology Corporation announced positive clinical and translational data at the 2025 Society for Immunotherapy of Cancer Annual Meeting. The data showcased immune-driven mechanisms and biomarkers explaining the strong clinical activity of their investigational therapies PDS0101 and PDS01ADC. These findings, part of a collaboration with the National Cancer Institute, highlight the therapies’ ability to activate immune responses, including natural killer and memory T cells, which are crucial for long-term tumor control. The results support the company’s regulatory strategy and ongoing clinical trials, reinforcing the scientific foundation of their immunotherapy platforms.

The most recent analyst rating on (PDSB) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.

PDS Biotechnology Seeks FDA Meeting for PDS0101 Approval

On October 29, 2025, PDS Biotechnology announced its request for a meeting with the FDA to explore an expedited approval pathway for its immunotherapy drug PDS0101, targeting HPV16-positive head and neck cancer. This decision follows promising results from the VERSATILE-002 trial, showing significant median progression-free and overall survival rates, and aims to amend the ongoing VERSATILE-003 trial to include progression-free survival as an earlier primary endpoint. This strategic move could potentially accelerate the drug’s availability to patients, positioning PDS Biotechnology as a leader in providing innovative cancer treatments.

The most recent analyst rating on (PDSB) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.